Thousands of people living with advanced prostate cancer will have access to a life-extending new treatment that can be taken at home from today, the UK health technology assessor, National Institute ...

The New York powerhouse has agreed to surrender its 11.7% interest in the HIV-focused company for $1.875 billion. Under terms ...

Pfizer’s stake in ViiV Healthcare will be taken over by Shiongi, another minority shareholder in the HIV medicines company.

This big pharma stock still faces significant challenges in the new year.

The healthcare giant has had trouble winning over investors in the past year despite an incredibly low valuation.

Meanwhile, during the WSJ event in Davos this week, Pfizer’s Bourla also took aim at the Trump administration’s moves to cut ...

Pfizer is paying $30 million to use Novavax’s adjuvant technology to improve the efficacy of two of the Big Pharma’s vaccine ...

Eli Lilly & Company LLY and Pfizer PFE are large-cap U.S. pharmaceutical leaders, each backed by diversified product ...

Facing the loss of exclusivity on key products, Pfizer has pulled forward its lead obesity asset into Phase III and targeted ...

The deal on drug prices between the US Administration and Pfizer will leave the margins of innovative pharma companies intact. Yet, benefits to consumers will be modest. Furthermore, prices for ...

By Yadarisa Shabong Jan 20 (Reuters) - Britain's GSK and Japan's Shionogi said on Tuesday that Pfizer will exit their HIV ...